Daxor (DXR) vs InspireMD (NSPR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Daxor (DXR) has outperformed InspireMD (NSPR) over the past year, losing 43.5% versus a loss of 72.0%. Over five years, DXR leads with a -32.3% price change compared with -85.1% for NSPR. Daxor is the larger company by market cap ($43.5 million vs $29.2 million), about 1.5 times the size, while InspireMD is growing revenue faster (+28.1% vs -8.4%).
Daxor converts more of its revenue into profit, with a net margin of -496.8% versus -543.3%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DXR | NSPR |
|---|---|---|
| Share price | $7.45 | $0.54 |
| Market cap | $43.49M | $29.23M |
| 1-day change | -7.33% | -12.97% |
| YTD return | -49.49% | -69.66% |
| 1-year return | -43.52% | -72.02% |
| 5-year return | -32.27% | -85.12% |
| P/E ratio (TTM) | 6.77 | — |
| EPS (TTM) | $1.10 | $-0.57 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.45M | $8.98M |
| Revenue growth (YoY) | -8.42% | +28.11% |
| Net income (latest FY) | $-7.19M | $-48.79M |
| Gross margin | 54.89% | 29.50% |
| Operating margin | -400.07% | -552.56% |
| Net margin | -496.81% | -543.33% |
| 52-week high | $14.76 | $2.17 |
| 52-week low | $6.94 | $0.43 |
| Distance from 52-week high | -49.53% | -75.12% |
| Analyst consensus | none | none |
| Avg. price target upside | +168.46% | +516.67% |
| Average volume | 22.43K | 234.68K |
| Shares outstanding | 5.84M | 54.13M |
| Employees | — | 127 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DXR has outperformed NSPR by 28.5 percentage points over the past year.
- Daxor is more profitable, keeping -496.8 cents of every revenue dollar as net income versus -543.3 cents for InspireMD.
- InspireMD grew revenue faster in its latest fiscal year (+28.11% vs -8.42%).
About Daxor
DXR stock →Daxor Corporation engages in medical instrumentation and biotechnology operations. It develops the BVA-100 Blood Volume Analyzer, an instrument that measures human blood volume, in conjunction with Volumex, a single-use radiopharmaceutical diagnostic injection and collection kit.
Health Care · Medical/Dental Instruments
About InspireMD
NSPR stock →InspireMD, Inc., a medical device company, focuses on the development and commercialization of products for the treatment of carotid artery disease and other vascular conditions in the United States, Germany, Italy, Russia, Poland, and internationally. It offers MicroNet, a biocompatible polymer mesh material for medical implants, as well as for treating plaque prolapse and embolization; CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Carotid Stent System; and SwitchGuard neuroprotection system to provide flow reversal of cerebral protection in carotid interventions, as well as treating acute stroke with tandem lesions.
Health Care · Medical/Dental Instruments · 127 employees
DXR vs NSPR FAQ
Which is bigger, Daxor or InspireMD?
Daxor (DXR) is larger, with a market capitalization of $43.49M compared with $29.23M for InspireMD (NSPR).
Which stock has performed better over the past year, DXR or NSPR?
DXR returned -43.52% over the past 12 months, compared with -72.02% for NSPR (price return, excluding dividends). Past performance does not predict future results.
Are Daxor and InspireMD in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.